fda glp-1 compounding warning letters october 2025 FDA Issues Warnings Against Illegal GLP-1 Marketing

FDA Drug Recalls and Warnings: Recalls for Compounded Semaglutide and Tirzepatide, Wegovy; Facility Warning Letters

26.39

★★★★☆4.8 (126)

Out of Shortage, Into Controversy: The Fight Over GLP-1 Compounding

26.54

★★★★★4.9 (98)

The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight-loss results, Retatrutide

26.71

★★★★★5.0 (157)

Pharmacovigilance Assessment of Compounded GLP-1 Receptor Agonists: Insights From the FDA Adverse Event Reporting System

20.67

★★★★★4.7 (84)

CDER Warning Letters Jump 50% in FY 2025 — What That Means for Industry

21.06

★★★★★4.9 (203)

FDA Targets Telehealth Compounded GLP-1 Marketing in New Warning Letters

28.88

★★★★★5.0 (176)

FDA is moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified

26.17

★★★★★4.8 (132)